Explore more publications!

US Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.

Press releases published on October 18, 2025

JointCommerce Launches A21+ ‘Household Targeting’ Solution for Connected TV Video Advertising
Barry I. Gold to Present Groundbreaking ‘We’re Overdosed’ Series at Frankfurt Buchmesse 2025
A Million Thanks Launches New Veteran Letter Request Program for Post-9/11 Veterans
Nirvana Recovery’s Integrated Model Leads Arizona’s Alcohol Fight
Evoq Technologies Appoints Benjamin A. Bakall, MD, PhD as Scientific Advisor and Principal Investigator
Evoq Technologies’ Breakthroughs in Retinal Diagnostics at AAO Annual Meeting
New Book: Experiencing Transcendence Reimagines Addiction & Trauma Recovery Moving Beyond Lifelong Struggle to Freedom
We’re Overdosed: From Opium to Opioids Reveals the Hidden Roots of Addiction
The Untold Story of America’s Opioid Epidemic Uncovers the Truth Behind the Crisis
KFSHRC Redefines Cancer Care Through Precision, Innovation, and Localized Advanced Therapies
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
 Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions